Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A three-drug regimen is turning heads in metastatic bladder cancer. Interim data from the TROPHY-U-01 trial show that combining sacituzumab govitecan, enfortumab vedotin, and zimberelimab achieved an 81% response rate in treatment-naive patients, with responses lasting nearly 17 months on average. Researchers say the findings support further exploration of antibody-drug conjugate combinations in urothelial carcinoma.
A three-drug combination is showing impressive early results in metastatic urothelial cancer (the most common type of bladder cancer). Interim data from the phase 1b portion of cohort 7 of the TROPHY-U-01 trial, presented at the 2026 ESMO Congress, found that sacituzumab govitecan (Trodelvy), enfortumab vedotin (Padcev), and zimberelimab produced an 81% objective response rate in 21 previously untreated patients — with tumor shrinkage observed in every evaluable patient.
Responses were not only common but durable. The median duration of response hit 16.7 months, and median progression-free survival reached 19.3 months. Median overall survival had not yet been reached at the time of analysis. The safety profile was manageable, though notable — two-thirds of patients experienced grade 3 or higher treatment-emergent adverse events, and one-third discontinued at least one drug due to side effects. No treatment-related deaths occurred.
By the Numbers
Why it matters: Metastatic urothelial cancer is notoriously difficult to treat, and first-line options remain limited. This triplet regimen — combining two antibody-drug conjugates with an immunotherapy — could open a new treatment avenue, with ongoing phase 2 and phase 3 trials set to further define its role.
